![](https://cdn.sanity.io/images/0vv8moc6/pharmtech/2b6495cc1c9eda73b83dc43c7e3fb48e6cf84ea8-1280x720.jpg?fit=crop&auto=format)
European Commission Approves BridgeBio Treatment for ATTR-CM
BridgeBio Pharma, of Palo Alto, Calif., has announced the European Commission (EC)’s marketing authorization approval for Beyonttra (acoramidis), for treatment of wild-type or variant transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM …